Pasithea Therapeutics Announces Intention to Commence a 4.0Million Tender Offer for its Common Stock at Price of 0.70 per Share in Cash

KTTA Stock  USD 2.56  0.24  8.57%   
About 54% of Pasithea Therapeutics' investors are presently thinking to get in. The analysis of the overall investor sentiment regarding Pasithea Therapeutics Corp suggests that some traders are interested. The current market sentiment, together with Pasithea Therapeutics' historical and current headlines, can help investors time the market. In addition, many technical investors use Pasithea Therapeutics stock news signals to limit their universe of possible portfolio assets.
  
Tender Offer Expected to Close Third Quarter of 2023PALO ALTO, Calif. and MIAMI, July 20, 2023 Pasithea Therapeutics Corp. , a biotechnology company focused on the discovery, research, and development of innovative treatments for central nervous system disorders, today announced that its Board of Directors has authorized the repurchase, through a 4.0 million tender offer , of up to approximately

Read at finance.yahoo.com
Yahoo News
  

Pasithea Therapeutics Investor Sentiment by Other News Outlets

Investor sentiment, mood or attitude towards Pasithea Therapeutics can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.

Pasithea Therapeutics Fundamental Analysis

We analyze Pasithea Therapeutics' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Pasithea Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Pasithea Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Cash Per Share

Cash Per Share Comparative Analysis

Pasithea Therapeutics is currently under evaluation in cash per share category among its peers. Cash per Share is a ratio of current cash on hands or in the banks of the company to a total number of shares outstanding. It is used to determine a firm's liquidity and is a good indicator of the overall financial health of a company. Value investors often compare this ratio to the current stock quote, and if it exceeds the stock price they would invest in it.

Pasithea Therapeutics Potential Pair-trading

One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Pasithea Therapeutics stock to make a market-neutral strategy. Peer analysis of Pasithea Therapeutics could also be used in its relative valuation, which is a method of valuing Pasithea Therapeutics by comparing valuation metrics with similar companies.

Peers

Pasithea Therapeutics Related Equities

ABVCABVC Biopharma   3.77   
0%
43.0%
VRAXVirax Biolabs   3.42   
0%
39.0%
RNXTRenovoRx   0.76   
0%
8.0%
KZRKezar Life   1.06   
12.0%
0%
MNOVMediciNova   1.51   
17.0%
0%
INDPIndaptus Therapeutics   2.06   
23.0%
0%
KRONKronos Bio   3.03   
35.0%
0%
KPRXKiora Pharmaceuticals   5.63   
65.0%
0%
QNRXQuoin Pharmaceuticals   6.06   
70.0%
0%
NTRBWNutriband Warrant   7.82   
90.0%
0%
FBRXForte Biosciences   8.54   
99.0%
0%
REVBRevelation Biosciences   8.62   
100.0%
0%

Complementary Tools for Pasithea Stock analysis

When running Pasithea Therapeutics' price analysis, check to measure Pasithea Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Pasithea Therapeutics is operating at the current time. Most of Pasithea Therapeutics' value examination focuses on studying past and present price action to predict the probability of Pasithea Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Pasithea Therapeutics' price. Additionally, you may evaluate how the addition of Pasithea Therapeutics to your portfolios can decrease your overall portfolio volatility.
Odds Of Bankruptcy
Get analysis of equity chance of financial distress in the next 2 years
Correlation Analysis
Reduce portfolio risk simply by holding instruments which are not perfectly correlated
Funds Screener
Find actively-traded funds from around the world traded on over 30 global exchanges